Marshall Wace
IMRX icon

Marshall Wace’s Immuneering IMRX Stock Holding History

Marshall Wace’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.5M Buy
1,996,585
+1,284,710
+180% +$6.59M 0.01% 957
2025
Q4 		$4.68M Buy
711,875
+440,571
+162% +$2.83M ﹤0.01% 1186
2025
Q3 		$1.9M Sell
271,304
-302,560
-53% -$1.57M ﹤0.01% 1650
2025
Q2 		$1.93M Sell
573,864
-234,105
-29% -$401K ﹤0.01% 1578
2025
Q1 		$1.23M Buy
807,969
+786,537
+3,670% +$1.43M ﹤0.01% 1692
2024
Q4 		$47.1K Buy
+21,432
New +$44.4K ﹤0.01% 2488
2024
Q3 		– Sell
-384,075
Closed -$492K – 2717
2024
Q2 		$492K Buy
+384,075
New +$631K ﹤0.01% 1963
2022
Q4 		– Sell
-67,160
Closed -$962K – 3159
2022
Q3 		$962K Buy
+67,160
New +$533K ﹤0.01% 2429
2021
Q4 		– Sell
-13,149
Closed -$349K – 4058
2021
Q3 		$349K Buy
+13,149
New +$353K ﹤0.01% 2580

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Marshall Wace's IMRX Position: Q1 2026 in Review

Marshall Wace increased its Immuneering (IMRX) stake by 180% in Q1 2026, buying an estimated $6.59M and bringing the position to 1,996,585 shares worth $10.5M. The position accounts for 0.01% of the portfolio, ranked #957.

Marshall Wace first reported a position in IMRX in Q3 2021 and has held it in 9 quarters since. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Marshall Wace held 1,996,585 shares of Immuneering worth $10.5M as of Q1 2026.
  • Marshall Wace bought 1,284,710 Immuneering shares in Q1 2026, an estimated $6.59M.
  • Immuneering made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #957 holding.
  • Marshall Wace first reported a position in Immuneering in Q3 2021 and has held it in 9 quarters since.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.